Table 9 |
|||||
|
Autoantibodies and fibromyalgia (FM) |
|||||
|
Reference |
Year of study |
Number of FM patients |
Number of control individuals |
Objective measure |
Findings |
|
|
|||||
|
Klein and colleagues [82] |
1992 |
50 |
?HC |
Antiserotonin |
Increased in FMS |
|
Antiganglioside |
Increased in FMS |
||||
|
Antiphospholipid |
Increased in FMS |
||||
|
Klein and Berg [81] |
1995 |
100 |
42 CFS, ?HC |
Antiserotonin |
Increased in CFS and FMS |
|
Antigangliosides |
Increased in CFS and FMS |
||||
|
Antiphospholipid |
Increased in CFS and FMS |
||||
|
Werle and colleagues [83] |
2001 |
203 |
64 |
Antiserotonin |
Increased |
|
Antithromboplastin |
Increased |
||||
|
Antiganglioside |
No difference |
||||
|
Gm1 |
No difference |
||||
|
Wilson and colleagues [84] |
1999 |
47 |
16 OA,12 RA, banked sera, 15 myositis, 30 RA, 30 SLE, 30 SSc |
Antipolymer antibody |
Increased in antipolymer antibodies, higher in severe versus mild |
|
Nishikai and colleagues [85] |
2001 |
125 |
114 CFS, ?psych, ?CTD |
Anti-68/48 kDa |
Increased in FMS and CFS |
|
Anti-45 kDa |
Increased in FMS and CFS |
||||
|
|
|||||
|
CFS, chronic fatigue syndrome; CTD, connective tissue disease; FMS, fibromyalgia syndrome; HC, healthy control individuals; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythmatosus; SSc, systemic sclerosis. |
|||||
|
Dadabhoy et al. Arthritis Research & Therapy 2008 10:211 doi:10.1186/ar2443 |
|||||